Abstract
Mammalian target of rapamycin (mTOR) is an evolutionarily conserved kinase that integrates signals from nutrients and growth factors for the coordinate regulation of many cellular processes, including proliferation and cell death. Constitutive mTOR signaling characterizes multiple human malignancies, and pharmacological inhibitors of mTOR such as the immunosuppressant rapamycin and some of its nonimmunosuppressive derivatives not only have been ascribed with promising anticancer properties in vitro and in vivo but are also being extensively evaluated in clinical trials. mTOR inhibition rapidly leads to the activation of autophagy, which most often exerts prosurvival effects, although in some cases it accompanies cell death. Thus, depending on the specific experimental setting (cell type, concentration, stimulation time, and presence of concurrent stimuli), rapamycin can activate/favor a wide spectrum of cellular responses/phenotypes, ranging from adaptation to stress and survival to cell death. The (at least partial) overlap among the biochemical and morphological responses triggered by rapamycin considerably complicates the study of cell death-associated variables. Moreover, rapamycin presumably triggers acute cell death mainly via off-target mechanisms. Here, we describe a set of assays that can be employed for the routine quantification of rapamycin-induced cell death in vitro, as well as a set of guidelines that should be applied for their correct interpretation.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsAbbreviations
- AnnV:
-
Annexin V
- ATCC:
-
American type culture collection
- BSA:
-
Bovine serum albumin
- CRTC1:
-
CREB-regulated transcription coactivator 1
- CV:
-
Crystal violet
- DAPI:
-
4′,6-Diamidino-2-phenylindole dihydrochloride
- dH2O:
-
Deionized water
- DiOC6(3):
-
3,3′-Dihexiloxalocarbocyanine iodide
- DTT:
-
Dithiothreitol
- EDTA:
-
Ethylenediaminetetraacetic acid
- EGFR:
-
Epidermal growth factor receptor
- FITC:
-
Fluorescein isothiocyanate
- FSC:
-
Forward scatter
- HBSS:
-
Hank’s balanced salt solution
- IARC:
-
International Agency for Research on Cancer
- IC50 :
-
Half maximal inhibitory concentration
- IM:
-
Inner mitochondrial membrane
- IMS:
-
Mitochondrial intermembrane space
- ∆ψ m :
-
Mitochondrial transmembrane potential
- MMP:
-
Mitochondrial membrane permeabilization
- mTOR:
-
Mammalian target of rapamycin
- NTP:
-
National Toxicology Program
- OM:
-
Outer mitochondrial membrane
- OSHA:
-
Occupational Safety and Health Administration
- PBS:
-
Phosphate-buffered saline
- PFA:
-
Paraformaldehyde
- PI:
-
Propidium iodide
- PI3K:
-
Phosphoinositide 3-kinase
- PLSCR1:
-
Phospholipid scramblase 1
- PMSF:
-
Phenylmethylsulfonyl fluoride
- PS:
-
Phosphatidylserine
- ROS:
-
Reactive oxygen species
- RT:
-
Room temperature
- SDS:
-
Sodium dodecylsulfate
- SF:
-
Surviving fraction
- siRNA:
-
Small interfering RNA
- SSC:
-
Side scatter
- TBS:
-
Tris-buffered saline
- TMRM:
-
Tetramethylrhodamine methyl ester
- TORC:
-
TOR complex
References
Sarbassov, D. D., Ali, S. M., and Sabatini, D. M. (2005) Growing roles for the mTOR pathway, Curr Opin Cell Biol 17, 596–603.
Guertin, D. A., and Sabatini, D. M. (2005) An expanding role for mTOR in cancer, Trends Mol Med 11, 353–361.
Law, B. K. (2005) Rapamycin: an anti-cancer immunosuppressant? Crit Rev Oncol Hematol 56, 47–60.
Faivre, S., Kroemer, G., and Raymond, E. (2006) Current development of mTOR inhibitors as anticancer agents, Nat Rev Drug Discov 5, 671–688.
Decker, T., Sandherr, M., Goetze, K., Oelsner, M., Ringshausen, I., and Peschel, C. (2009) A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL, Ann Hematol 88, 221–227.
Kapoor, A., and Figlin, R. A. (2009) Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma, Cancer 115, 3618–3630.
Loewith, R., Jacinto, E., Wullschleger, S., Lorberg, A., Crespo, J. L., Bonenfant, D., Oppliger, W., Jenoe, P., and Hall, M. N. (2002) Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control, Mol Cell 10, 457–468.
Bhaskar, P. T., and Hay, N. (2007) The two TORCs and Akt, Dev Cell 12, 487–502.
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J. H., Hsu, P. P., Bagley, A. F., Markhard, A. L., and Sabatini, D. M. (2006) Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB, Mol Cell 22, 159–168.
Zeng, Z., Sarbassov dos, D., Samudio, I. J., Yee, K. W., Munsell, M. F., Ellen Jackson, C., Giles, F. J., Sabatini, D. M., Andreeff, M., and Konopleva, M. (2007) Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML, Blood 109, 3509–3512.
Castedo, M., Ferri, K. F., and Kroemer, G. (2002) Mammalian target of rapamycin (mTOR): pro- and anti-apoptotic, Cell Death Differ 9, 99–100.
Galluzzi, L., Maiuri, M. C., Vitale, I., Zischka, H., Castedo, M., Zitvogel, L., and Kroemer, G. (2007) Cell death modalities: classification and pathophysiological implications, Cell Death Differ 14, 1237–1243.
Kroemer, G., Galluzzi, L., Vandenabeele, P., Abrams, J., Alnemri, E. S., Baehrecke, E. H., Blagosklonny, M. V., El-Deiry, W. S., Golstein, P., Green, D. R., Hengartner, M., Knight, R. A., Kumar, S., Lipton, S. A., Malorni, W., Nunez, G., Peter, M. E., Tschopp, J., Yuan, J., Piacentini, M., Zhivotovsky, B., and Melino, G. (2009) Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009, Cell Death Differ 16, 3–11.
Garrido, C., Galluzzi, L., Brunet, M., Puig, P. E., Didelot, C., and Kroemer, G. (2006) Mechanisms of cytochrome c release from mitochondria, Cell Death Differ 13, 1423–1433.
Kroemer, G., Galluzzi, L., and Brenner, C. (2007) Mitochondrial membrane permeabilization in cell death, Physiol Rev 87, 99–163.
Klionsky, D. J., Abeliovich, H., Agostinis, P., Agrawal, D. K., Aliev, G., Askew, D. S., Baba, M., Baehrecke, E. H., Bahr, B. A., Ballabio, A., Bamber, B. A., Bassham, D. C., Bergamini, E., Bi, X., Biard-Piechaczyk, M., Blum, J. S., Bredesen, D. E., Brodsky, J. L., Brumell, J. H., Brunk, U. T., Bursch, W., Camougrand, N., Cebollero, E., Cecconi, F., Chen, Y., Chin, L. S., Choi, A., Chu, C. T., Chung, J., Clarke, P. G., Clark, R. S., Clarke, S. G., Clave, C., Cleveland, J. L., Codogno, P., Colombo, M. I., Coto-Montes, A., Cregg, J. M., Cuervo, A. M., Debnath, J., Demarchi, F., Dennis, P. B., Dennis, P. A., Deretic, V., Devenish, R. J., Di Sano, F., Dice, J. F., Difiglia, M., Dinesh-Kumar, S., Distelhorst, C. W., Djavaheri-Mergny, M., Dorsey, F. C., Droge, W., Dron, M., Dunn, W. A., Jr., Duszenko, M., Eissa, N. T., Elazar, Z., Esclatine, A., Eskelinen, E. L., Fesus, L., Finley, K. D., Fuentes, J. M., Fueyo, J., Fujisaki, K., Galliot, B., Gao, F. B., Gewirtz, D. A., Gibson, S. B., Gohla, A., Goldberg, A. L., Gonzalez, R., Gonzalez-Estevez, C., Gorski, S., Gottlieb, R. A., Haussinger, D., He, Y. W., Heidenreich, K., Hill, J. A., Hoyer-Hansen, M., Hu, X., Huang, W. P., Iwasaki, A., Jaattela, M., Jackson, W. T., Jiang, X., Jin, S., Johansen, T., Jung, J. U., Kadowaki, M., Kang, C., Kelekar, A., Kessel, D. H., Kiel, J. A., Kim, H. P., Kimchi, A., Kinsella, T. J., Kiselyov, K., Kitamoto, K., Knecht, E., Komatsu, M., Kominami, E., Kondo, S., Kovacs, A. L., Kroemer, G., Kuan, C. Y., Kumar, R., Kundu, M., Landry, J., Laporte, M., Le, W., Lei, H. Y., Lenardo, M. J., Levine, B., Lieberman, A., Lim, K. L., Lin, F. C., Liou, W., Liu, L. F., Lopez-Berestein, G., Lopez-Otin, C., Lu, B., Macleod, K. F., Malorni, W., Martinet, W., Matsuoka, K., Mautner, J., Meijer, A. J., Melendez, A., Michels, P., Miotto, G., Mistiaen, W. P., Mizushima, N., Mograbi, B., Monastyrska, I., Moore, M. N., Moreira, P. I., Moriyasu, Y., Motyl, T., Munz, C., Murphy, L. O., Naqvi, N. I., Neufeld, T. P., Nishino, I., Nixon, R. A., Noda, T., Nurnberg, B., Ogawa, M., Oleinick, N. L., Olsen, L. J., Ozpolat, B., Paglin, S., Palmer, G. E., Papassideri, I., Parkes, M., Perlmutter, D. H., Perry, G., Piacentini, M., Pinkas-Kramarski, R., Prescott, M., Proikas-Cezanne, T., Raben, N., Rami, A., Reggiori, F., Rohrer, B., Rubinsztein, D. C., Ryan, K. M., Sadoshima, J., Sakagami, H., Sakai, Y., Sandri, M., Sasakawa, C., Sass, M., Schneider, C., Seglen, P. O., Seleverstov, O., Settleman, J., Shacka, J. J., Shapiro, I. M., Sibirny, A., Silva-Zacarin, E. C., Simon, H. U., Simone, C., Simonsen, A., Smith, M. A., Spanel-Borowski, K., Srinivas, V., Steeves, M., Stenmark, H., Stromhaug, P. E., Subauste, C. S., Sugimoto, S., Sulzer, D., Suzuki, T., Swanson, M. S., Tabas, I., Takeshita, F., Talbot, N. J., Talloczy, Z., Tanaka, K., Tanida, I., Taylor, G. S., Taylor, J. P., Terman, A., Tettamanti, G., Thompson, C. B., Thumm, M., Tolkovsky, A. M., Tooze, S. A., Truant, R., Tumanovska, L. V., Uchiyama, Y., Ueno, T., Uzcategui, N. L., van der Klei, I., Vaquero, E. C., Vellai, T., Vogel, M. W., Wang, H. G., Webster, P., Wiley, J. W., Xi, Z., Xiao, G., Yahalom, J., Yang, J. M., Yap, G., Yin, X. M., Yoshimori, T., Yu, L., Yue, Z., Yuzaki, M., Zabirnyk, O., Zheng, X., Zhu, X., and Deter, R. L. (2008) Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes, Autophagy 4, 151–175.
Golstein, P., and Kroemer, G. (2005) Redundant cell death mechanisms as relics and backups, Cell Death Differ 12 Suppl 2, 1490–1496.
Golstein, P., and Kroemer, G. (2007) Cell death by necrosis: towards a molecular definition, Trends Biochem Sci 32, 37–43.
Galluzzi, L., Blomgren, K., and Kroemer, G. (2009) Mitochondrial membrane permeabilization in neuronal injury, Nat Rev Neurosci 10, 481–494.
Galluzzi, L., Vicencio, J. M., Kepp, O., Tasdemir, E., Maiuri, M. C., and Kroemer, G. (2008) To die or not to die: that is the autophagic question, Curr Mol Med 8, 78–91.
Kroemer, G., and Levine, B. (2008) Autophagic cell death: the story of a misnomer, Nat Rev Mol Cell Biol 9, 1004–1010.
Boya, P., Gonzalez-Polo, R. A., Casares, N., Perfettini, J. L., Dessen, P., Larochette, N., Metivier, D., Meley, D., Souquere, S., Yoshimori, T., Pierron, G., Codogno, P., and Kroemer, G. (2005) Inhibition of macroautophagy triggers apoptosis, Mol Cell Biol 25, 1025–1040.
Gonzalez-Polo, R. A., Boya, P., Pauleau, A. L., Jalil, A., Larochette, N., Souquere, S., Eskelinen, E. L., Pierron, G., Saftig, P., and Kroemer, G. (2005) The apoptosis/autophagy paradox: autophagic vacuolization before apoptotic death, J Cell Sci 118, 3091–3102.
Galluzzi, L., Kepp, O., and Kroemer, G. (2009) RIP kinases initiate programmed necrosis, J Mol Cell Biol
Galluzzi, L., and Kroemer, G. (2008) Necroptosis: a specialized pathway of programmed necrosis, Cell 135, 1161–1163.
Galluzzi, L., Aaronson, S. A., Abrams, J., Alnemri, E. S., Andrews, D. W., Baehrecke, E. H., Bazan, N. G., Blagosklonny, M. V., Blomgren, K., Borner, C., Bredesen, D. E., Brenner, C., Castedo, M., Cidlowski, J. A., Ciechanover, A., Cohen, G. M., De Laurenzi, V., De Maria, R., Deshmukh, M., Dynlacht, B. D., El-Deiry, W. S., Flavell, R. A., Fulda, S., Garrido, C., Golstein, P., Gougeon, M. L., Green, D. R., Gronemeyer, H., Hajnoczky, G., Hardwick, J. M., Hengartner, M. O., Ichijo, H., Jaattela, M., Kepp, O., Kimchi, A., Klionsky, D. J., Knight, R. A., Kornbluth, S., Kumar, S., Levine, B., Lipton, S. A., Lugli, E., Madeo, F., Malomi, W., Marine, J. C., Martin, S. J., Medema, J. P., Mehlen, P., Melino, G., Moll, U. M., Morselli, E., Nagata, S., Nicholson, D. W., Nicotera, P., Nunez, G., Oren, M., Penninger, J., Pervaiz, S., Peter, M. E., Piacentini, M., Prehn, J. H., Puthalakath, H., Rabinovich, G. A., Rizzuto, R., Rodrigues, C. M., Rubinsztein, D. C., Rudel, T., Scorrano, L., Simon, H. U., Steller, H., Tschopp, J., Tsujimoto, Y., Vandenabeele, P., Vitale, I., Vousden, K. H., Youle, R. J., Yuan, J., Zhivotovsky, B., and Kroemer, G. (2009) Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes, Cell Death Differ 16, 1093–1107.
Galluzzi, L., Joza, N., Tasdemir, E., Maiuri, M. C., Hengartner, M., Abrams, J. M., Tavernarakis, N., Penninger, J., Madeo, F., and Kroemer, G. (2008) No death without life: vital functions of apoptotic effectors, Cell Death Differ 15, 1113–1123.
Ferri, K. F., and Kroemer, G. (2001) Mitochondria – the suicide organelles, Bioessays 23, 111–115.
Ravagnan, L., Roumier, T., and Kroemer, G. (2002) Mitochondria, the killer organelles and their weapons, J Cell Physiol 192, 131–137.
Brenner, C., and Grimm, S. (2006) The permeability transition pore complex in cancer cell death, Oncogene 25, 4744–4756.
Galluzzi, L., Vitale, I., Kepp, O., Seror, C., Hangen, E., Perfettini, J. L., Modjtahedi, N., and Kroemer, G. (2008) Methods to dissect mitochondrial membrane permeabilization in the course of apoptosis, Methods Enzymol 442, 355–374.
Galluzzi, L., Zamzami, N., de La Motte Rouge, T., Lemaire, C., Brenner, C., and Kroemer, G. (2007) Methods for the assessment of mitochondrial membrane permeabilization in apoptosis, Apoptosis 12, 803–813.
Metivier, D., Dallaporta, B., Zamzami, N., Larochette, N., Susin, S. A., Marzo, I., and Kroemer, G. (1998) Cytofluorometric detection of mitochondrial alterations in early CD95/Fas/APO-1-triggered apoptosis of Jurkat T lymphoma cells. Comparison of seven mitochondrion-specific fluorochromes, Immunol Lett 61, 157–163.
Petit, P. X., Lecoeur, H., Zorn, E., Dauguet, C., Mignotte, B., and Gougeon, M. L. (1995) Alterations in mitochondrial structure and function are early events of dexamethasone-induced thymocyte apoptosis, J Cell Biol 130, 157–167.
Zamzami, N., Marchetti, P., Castedo, M., Decaudin, D., Macho, A., Hirsch, T., Susin, S. A., Petit, P. X., Mignotte, B., and Kroemer, G. (1995) Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death, J Exp Med 182, 367–377.
Zamzami, N., Marchetti, P., Castedo, M., Zanin, C., Vayssiere, J. L., Petit, P. X., and Kroemer, G. (1995) Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo, J Exp Med 181, 1661–1672.
Inoue, S., Browne, G., Melino, G., and Cohen, G. M. (2009) Ordering of caspases in cells undergoing apoptosis by the intrinsic pathway, Cell Death Differ 16, 1053–1061.
Kroemer, G., and Martin, S. J. (2005) Caspase-independent cell death, Nat Med 11, 725–730.
Kroemer, G., and Jaattela, M. (2005) Lysosomes and autophagy in cell death control, Nat Rev Cancer 5, 886–897.
Martin, S. J., Reutelingsperger, C. P., McGahon, A. J., Rader, J. A., van Schie, R. C., LaFace, D. M., and Green, D. R. (1995) Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl, J Exp Med 182, 1545–1556.
Wu, Y., Tibrewal, N., and Birge, R. B. (2006) Phosphatidylserine recognition by phagocytes: a view to a kill, Trends Cell Biol 16, 189–197.
Naito, M., Nagashima, K., Mashima, T., and Tsuruo, T. (1997) Phosphatidylserine externalization is a downstream event of interleukin-1 beta-converting enzyme family protease activation during apoptosis, Blood 89, 2060–2066.
Zhuang, J., and Cohen, G. M. (1998) Release of mitochondrial cytochrome c is upstream of caspase activation in chemical-induced apoptosis in human monocytic tumour cells, Toxicol Lett 102–103, 121–129.
Bailey, K., Cook, H. W., and McMaster, C. R. (2005) The phospholipid scramblase PLSCR1 increases UV induced apoptosis primarily through the augmentation of the intrinsic apoptotic pathway and independent of direct phosphorylation by protein kinase C delta, Biochim Biophys Acta 1733, 199–209.
Smrz, D., Lebduska, P., Draberova, L., Korb, J., and Draber, P. (2008) Engagement of phospholipid scramblase 1 in activated cells: implication for phosphatidylserine externalization and exocytosis, J Biol Chem 283, 10904–10918.
Balasubramanian, K., Mirnikjoo, B., and Schroit, A. J. (2007) Regulated externalization of phosphatidylserine at the cell surface: implications for apoptosis, J Biol Chem 282, 18357–18364.
Williamson, P., Christie, A., Kohlin, T., Schlegel, R. A., Comfurius, P., Harmsma, M., Zwaal, R. F., and Bevers, E. M. (2001) Phospholipid scramblase activation pathways in lymphocytes, Biochemistry 40, 8065–8072.
Vermes, I., Haanen, C., Steffens-Nakken, H., and Reutelingsperger, C. (1995) A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V, J Immunol Methods 184, 39–51.
Foster, D. A., and Toschi, A. (2009) Targeting mTOR with rapamycin: one dose does not fit all, Cell Cycle 8, 1026–1029.
Tasdemir, E., Galluzzi, L., Maiuri, M. C., Criollo, A., Vitale, I., Hangen, E., Modjtahedi, N., and Kroemer, G. (2008) Methods for assessing autophagy and autophagic cell death, Methods Mol Biol 445, 29–76.
Kabeya, Y., Mizushima, N., Ueno, T., Yamamoto, A., Kirisako, T., Noda, T., Kominami, E., Ohsumi, Y., and Yoshimori, T. (2000) LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing, EMBO J 19, 5720–5728.
Tanida, I., Ueno, T., and Kominami, E. (2004) Human light chain 3/MAP1LC3B is cleaved at its carboxyl-terminal Met121 to expose Gly120 for lipidation and targeting to autophagosomal membranes, J Biol Chem 279, 47704–47710.
Ichimura, Y., Kirisako, T., Takao, T., Satomi, Y., Shimonishi, Y., Ishihara, N., Mizushima, N., Tanida, I., Kominami, E., Ohsumi, M., Noda, T., and Ohsumi, Y. (2000) A ubiquitin-like system mediates protein lipidation, Nature 408, 488–492.
Nakatogawa, H., Ichimura, Y., and Ohsumi, Y. (2007) Atg8, a ubiquitin-like protein required for autophagosome formation, mediates membrane tethering and hemifusion, Cell 130, 165–178.
Bjorkoy, G., Lamark, T., Brech, A., Outzen, H., Perander, M., Overvatn, A., Stenmark, H., and Johansen, T. (2005) p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death, J Cell Biol 171, 603–614.
Komatsu, M., Wang, Q. J., Holstein, G. R., Friedrich, V. L., Jr., Iwata, J., Kominami, E., Chait, B. T., Tanaka, K., and Yue, Z. (2007) Essential role for autophagy protein Atg7 in the maintenance of axonal homeostasis and the prevention of axonal degeneration, Proc Natl Acad Sci USA 104, 14489–14494.
Tasdemir, E., Maiuri, M. C., Galluzzi, L., Vitale, I., Djavaheri-Mergny, M., D’Amelio, M., Criollo, A., Morselli, E., Zhu, C., Harper, F., Nannmark, U., Samara, C., Pinton, P., Vicencio, J. M., Carnuccio, R., Moll, U. M., Madeo, F., Paterlini-Brechot, P., Rizzuto, R., Szabadkai, G., Pierron, G., Blomgren, K., Tavernarakis, N., Codogno, P., Cecconi, F., and Kroemer, G. (2008) Regulation of autophagy by cytoplasmic p53, Nat Cell Biol 10, 676–687.
Vignot, S., Faivre, S., Aguirre, D., and Raymond, E. (2005) mTOR-targeted therapy of cancer with rapamycin derivatives, Ann Oncol 16, 525–537.
Schroit, A. J., and Zwaal, R. F. (1991) Transbilayer movement of phospholipids in red cell and platelet membranes, Biochim Biophys Acta 1071, 313–329.
Acknowledgments
GK is supported by the Ligue Nationale contre le Cancer (Equipe labellisée), Agence Nationale de la Recherche, Cancéropôle Ile-de-France, Fondation pour la Recherche Médicale, Institut National du Cancer, European Commission (Active p53, Apo-Sys, RIGHT, TransDeath, ChemoRes, ApopTrain), and Fondation pour la Recherche Médicale. LG, EM, and OK are supported by Apo-Sys, the ApopTrain Marie Curie training network of the European Union, and INSERM, respectively.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Galluzzi, L. et al. (2012). Evaluation of Rapamycin-Induced Cell Death. In: Weichhart, T. (eds) mTOR. Methods in Molecular Biology, vol 821. Humana Press. https://doi.org/10.1007/978-1-61779-430-8_9
Download citation
DOI: https://doi.org/10.1007/978-1-61779-430-8_9
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-61779-429-2
Online ISBN: 978-1-61779-430-8
eBook Packages: Springer Protocols